COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00586625
Recruitment Status : Completed
First Posted : January 4, 2008
Results First Posted : November 11, 2009
Last Update Posted : February 15, 2013
Information provided by (Responsible Party):
Bausch & Lomb Incorporated

Brief Summary:
Safety study for bepotastine besilate ophthalmic solution in normal volunteers

Condition or disease Intervention/treatment Phase
Allergic Conjunctivitis Drug: Bepreve Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 861 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : October 2007
Actual Primary Completion Date : May 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Bepotastine

Arm Intervention/treatment
Experimental: Bepreve
bepotastine besilate ophthalmic solution 1.5%
Drug: Bepreve
One drop, both eyes, twice a day

Placebo Comparator: Placebo
Drug: Placebo
One drop, both eyes, twice a day

Primary Outcome Measures :
  1. Ocular Comfort [ Time Frame: Day 8 & Day 22 ]

    A 4-step grading scale with half unit (1-step) increments allowed:

    0=Comfortable;discomfort absent; 1.0=Generally comfortable; mild discomfort; 2.0=Some discomfort but tolerable; moderate comfort; 3.0=Severely uncomfortable or intolerable

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects must be at least 3 years of age, and have ocular health within normal limits

Exclusion Criteria:

  • No active ocular disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00586625

Sponsors and Collaborators
Bausch & Lomb Incorporated
Layout table for investigator information
Study Director: Tim McNamara, PharmD ISTA Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Bausch & Lomb Incorporated Identifier: NCT00586625    
Other Study ID Numbers: CL-SAF-0405071-P
First Posted: January 4, 2008    Key Record Dates
Results First Posted: November 11, 2009
Last Update Posted: February 15, 2013
Last Verified: February 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Immune System Diseases
Bepotastine besilate
Anti-Allergic Agents